Vaderis raises $152M Series B for late-stage HHT drug trial
What's the deal? Vaderis TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised an oversubscribed $152 million Series B to fund a late-stage trial of engasertib, an oral treatment for hereditary haemorrhagic telangiectasia. TCGXDealroom has a profile for this one. Try Dealroom → co-led the round with Goldman Sachs Alternatives, while new backers including Omega FundsDealroom has a profile for this one. Try Dealroom →, EQT Life SciencesDealroom has a profile for this one. Try Dealroom → and Perceptive Advisors joined existing investors MedicxiDealroom has a profile for this one. Try Dealroom → and Droia Oncology VenturesDealroom has a profile for this one. Try Dealroom →.
Why now? Vaderis has launched its Phase 3 study and plans to use some proceeds to support potential approvals in the US and other markets. Its website describes the company as focused on treatments for HHT and other rare vascular diseases.
What could go wrong? Massachusetts-based Diagonal Therapeutics and Atavistik Bio are also testing therapies aimed at related vascular biology.
Read more: Fierce Biotech
Image credit: Vaderis Therapeutics
